Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 81

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 81
---
 157        (625  
  Cash and cash equivalents – End of period                                               16,393       6,678       16,393                                6,678      10,190  

Operating
Activities

Cash
used by operating activities was $3.0 million for the three-month period ended December 31, 2024, as compared to $1.2 million in the
same period in 2023. This $1.8 million increase in operating cash outflows is attributed primarily to:

  An                                                                                                  
  An                                                                                                  
  An                                                                                                  

Cash
used by operating activities was $14.6 million for the twelve-month period ended December 31, 2024, as compared to $2.6 million in the
same period in 2023. This $12.0 million increase in operating cash outflows is attributed primarily to:

  An                                                                                          
  An                                                                                          
  An                                                                                          
  A                                                                                           

Cash
used by operating activities was $2.6 million for the twelve-month period ended December 31, 2023, as compared to cash provided by of
$5.2 million in the same period in 2022. This $7.8 million increase in operating cash outflows is attributed primarily to:

  A                                         

  An                                                                                         

  An                                                                                       

  A                                                                        

  A                                          

  59  

Investing
activities

Cash
provided by investing activities totaled $25.2 million for the year ended December 31, 2024, as compared to cash used of $0.7 million
in the same period in 2023. This $25.9 million increase in cash flows provided by investing activities is primarily related to the cash
acquired as part of the Transaction of $26.0 million and a $0.1 million reduction in purchases of property and equipment.

Cash
used in investing activities totaled $0.7 million for the year ended December 31, 2023, as compared to $0.3 million for the year ended
December 31, 2022. This $0.4 million increase in the cash used in investing activities is primarily related to the purchase of property
and equipment of $0.4 million.

Financing
activities

Cash
used in financing activities totaled $0.6 million for the year ended December 31, 2024, as compared to $0.4 million for the year ended
December 31, 202